Search
Descriptor English: Nivolumab
Descriptor Spanish: Nivolumab
Descriptor nivolumab
Entry term(s) BMS 936558
BMS-936558
BMS936558
MDX 1106
MDX-1106
MDX1106
ONO 4538
ONO-4538
ONO4538
Opdivo
Scope note: Anticuerpo monoclonal de inmunoglobulina G4 totalmente humanizado obtenido por ingeniería genética que se une al RECEPTOR 1 DE LA MUERTE CELULAR PROGRAMADA y activa una respuesta inmunitaria contra las células tumorales. Se usa en monoterapia o en combinación con IPILIMUMAB para el tratamiento del MELANOMA maligno avanzado. También se usa en el tratamiento del CARCINOMA PULMONAR NO MICROCÍTICO avanzado o recidivante, del CARCINOMA DE CÉLULAS RENALES y del LINFOMA DE HODGKIN.
Descriptor Portuguese: Nivolumabe
Descriptor French: Nivolumab
Entry term(s): BMS 936558
BMS-936558
BMS936558
MDX 1106
MDX-1106
MDX1106
ONO 4538
ONO-4538
ONO4538
Opdivo
Tree number(s): D12.776.124.486.485.114.224.060.829
D12.776.124.790.651.114.224.060.829
D12.776.377.715.548.114.224.200.829
RDF Unique Identifier: https://id.nlm.nih.gov/mesh/D000077594
Scope note: A genetically engineered, fully humanized immunoglobulin G4 monoclonal antibody that binds to the PD-1 RECEPTOR, activating an immune response to tumor cells. It is used as monotherapy or in combination with IPILIMUMAB for the treatment of advanced malignant MELANOMA. It is also used in the treatment of advanced or recurring NON-SMALL CELL LUNG CANCER; RENAL CELL CARCINOMA; and HODGKIN'S LYMPHOMA.
Allowable Qualifiers: AD administration & dosage
AE adverse effects
AN analysis
BI biosynthesis
BL blood
CF cerebrospinal fluid
CH chemistry
CL classification
DE drug effects
EC economics
GE genetics
HI history
IM immunology
IP isolation & purification
ME metabolism
PD pharmacology
PH physiology
PK pharmacokinetics
PO poisoning
RE radiation effects
TO toxicity
TU therapeutic use
UL ultrastructure
UR urine
Pharm Action: Antineoplastic Agents, Immunological
Registry Number: 31YO63LBSN
Public MeSH Note: 2019; NIVOLUMAB was indexed under ANTIBODIES, MONOCLONAL 2010-2018
History Note: 2019 (2010)
DeCS ID: 57701
Unique ID: D000077594
Documents indexed in the Virtual Health Library (VHL): Click here to access the VHL documents
Date Established: 2019/01/01
Date of Entry: 2018/07/09
Revision Date: 2018/06/19
Nivolumab - Preferred
Concept UI M0585694
Scope note A genetically engineered, fully humanized immunoglobulin G4 monoclonal antibody that binds to the PD-1 RECEPTOR, activating an immune response to tumor cells. It is used as monotherapy or in combination with IPILIMUMAB for the treatment of advanced malignant MELANOMA. It is also used in the treatment of advanced or recurring NON-SMALL CELL LUNG CANCER; RENAL CELL CARCINOMA; and HODGKIN'S LYMPHOMA.
Preferred term Nivolumab
Opdivo - Narrower
Concept UI M000602504
Preferred term Opdivo
ONO-4538 - Narrower
Concept UI M000641020
Preferred term ONO-4538
Entry term(s) ONO 4538
ONO4538
MDX-1106 - Narrower
Concept UI M0548933
Preferred term MDX-1106
Entry term(s) MDX 1106
MDX1106
BMS-936558 - Narrower
Concept UI M000641019
Preferred term BMS-936558
Entry term(s) BMS 936558
BMS936558



We want your feedback on the new DeCS / MeSH website

We invite you to complete a survey that will take no more than 3 minutes.

Go to survey